quoinpharma.com (QNRX) - Long-Term Debt to Capital Coefficient
The share price history of Quoin Pharmaceuticals (QNRX) on the GURU.Markets platform serves as an indicator for a brand that has earned physician recognition for aiding individuals with rare epidermal pathologies and maintains a flawless image within scientific circles. The current figure is 0.00. The business relies on precision medicine, creating unique agents to correct genetic protein deficiencies to relieve patients of physical suffering.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_QNRX_-_Quoin-Pharmaceuticals_-_Long-Term-Debt-to-Capital "QNRX: Quoin Pharma Long-Term Debt to Capital 07/04/2022 - 11/01/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Quoin Pharmaceuticals Ltd (QNRX)
Developing therapies for rare skin diseases requires significant investment in clinical trials. The current long-term debt-to-equity ratio reflects the proportion of borrowed funds with a maturity of over one year relative to equity. This metric measures financial leverage and the stability of the startup's funding structure. Comparing this ratio to US industry norms allows for an assessment of the risk of overpaying for the asset. This is critically important for the real-time assessment of the debt load of Quoin Pharmaceuticals (QNRX).